SNSE - Sensei gains FDA IND clearance for solid tumors candidate
2023-04-20 08:18:28 ET
- Sensei Biotherapeutics ( NASDAQ: SNSE ) received US FDA approval for its Investigational New Drug ( IND ) application for SNS-101, an antibody for solid tumors.
- The company will now proceed with a phase 1 trial of SNS-101 as both monotherapy and in combination with Regeneron Pharmaceuticals' ( REGN ) PD-1 inhibitor Libtayo (cemiplimab).
- The first patient in the trial is expected to be dosed mid year.
- Phase 1 will be compromise a dose escalation to help determine a recommended dose for phase 2. SNS-101 will be administered as an infusion every three weeks.
- SNS-101 is a monoclonal IgG1 antibody designed to selectively block the VISTA checkpoint in tumors .
- Seeking Alpha's Quant Rating has viewed Sensei ( SNSE ) as a hold since December 2022 .
For further details see:
Sensei gains FDA IND clearance for solid tumors candidate